ヘパリン起因性血小板減少症の世界市場：2025年～2033年

世界のヘパリン起因性血小板減少症市場は、2024年に103億7,000万米ドルに達し、2033年までには164億8,000万米ドルに達すると予測され、予測期間中の2025年から2033年のCAGRは5.3%で成長する見込みです。

ヘパリン起因性血小板減少症（HIT）とは、血栓の予防や治療に一般的に使用される抗凝固剤であるヘパリンにさらされた一部の人に起こる、免疫介在性の重篤な副作用です。HITは血小板数の著しい減少（血小板減少）を特徴とし、典型的にはヘパリン曝露後5日から10日で発症しますが、以前に感作された患者ではもっと早く発症することもあります。

ヘパリン起因性血小板減少症（HIT）は、血栓性合併症のリスクを軽減するために迅速かつ効果的な治療を必要とします。主要なアプローチとしては、あらゆる形態のヘパリンを中止し、代替抗凝固療法を開始することです。

市場力学：

促進要因と抑制要因

ヘパリン使用量の増加

HITの有病率はヘパリン投与と直接相関しているため、ヘパリンの使用増加はヘパリン起因性血小板減少症（HIT）市場を大きく牽引すると予想されます。ヘパリンは、手術や心血管疾患の治療など、さまざまな医療現場で広く使用されている抗凝固剤です。血栓塞栓症の予防や治療に有効であることからヘパリンの需要が高まるにつれ、HITの発生率も増加すると考えられます。この発生率の増加により、効果的な治療オプションが必要となり、HIT治療市場が拡大します。

さらに、HITに特化した新しい治療薬や抗凝固薬の研究開発が進んでいることも、市場の成長をさらに後押しすると考えられています。ヘルスケアプロバイダーは、HITのタイムリーな診断と管理を通じて患者の転帰を改善することに注力しており、ヘパリンの使用が増加することで、この分野での効果的な治療ソリューションに対する需要が高まると思われます。

疾患に対する認知度の低さ

医療従事者も患者も、この深刻な疾患について十分な知識を持たないことが多いため、認知度の低さがヘパリン起因性血小板減少症（HIT）市場の大きな妨げになると予想されます。さらに、HITの管理は複雑であるため、代替抗凝固薬やモニタリング・プロトコルに関する専門的な知識が必要であり、医療従事者が十分な訓練を受けていない環境では困難な場合があります。その結果、このような限られた認識により、効果的な治療に対する需要が減少し、HIT管理のための包括的なケア戦略の開発が妨げられることで、市場の成長が制限される可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • ヘパリンの使用増加
  • 抑制要因
    • 病気に対する認識の低さ
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 タイプ別

• アルガトロバン
• レピルジン

第7章 投与経路別

• 非経口
• 経口

第8章 エンドユーザー別

• 病院
• 専門クリニック
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Pfizer Inc.
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 過去および予測の製品販売
    • 製品販売量
  • 財務概要
    • 会社の収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Novartis AG
• Eagle Pharmaceuticals, Inc.
• Mitsubishi Chemical Group Corporation
• GLAND PHARMA Ltd.
• Teva Pharmaceutical Industries Ltd.
• Verolax Therapeutics

第12章 付録

The global heparin induced thrombocytopenia market reached US$ 10.37 billion in 2024 and is expected to reach US$ 16.48 billion by 2033, growing at a CAGR of 5.3% during the forecast period 2025-2033.

Heparin-induced thrombocytopenia (HIT) is a serious immune-mediated adverse reaction that occurs in some individuals exposed to heparin, an anticoagulant commonly used to prevent and treat blood clots. HIT is characterized by a significant drop in platelet count (thrombocytopenia), typically occurring 5 to 10 days after heparin exposure, although it can happen sooner in patients who have been previously sensitized.

Heparin-induced thrombocytopenia (HIT) requires prompt and effective treatment to mitigate the risk of thrombotic complications. The primary approach involves discontinuing all forms of heparin and initiating alternative anticoagulation therapies.

Market Dynamics: Drivers & Restraints

Increasing usage of heparin

The increasing use of heparin is expected to drive the heparin-induced thrombocytopenia (HIT) market significantly, as the prevalence of HIT is directly correlated with heparin administration. Heparin is a widely used anticoagulant in various medical settings, including surgeries and treatment of cardiovascular diseases. As the demand for heparin rises due to its effectiveness in preventing and treating thromboembolic events, the incidence of HIT is also likely to increase. This growing incidence necessitates effective treatment options, thereby expanding the HIT treatment market.

Additionally, the ongoing research and development of new therapies and anticoagulants specifically targeting HIT will further boost market growth. With healthcare providers focusing on improving patient outcomes through timely diagnosis and management of HIT, the increasing use of heparin will create a robust demand for effective treatment solutions in this segment.

Limited awareness of the disease

Limited awareness is expected to hinder the heparin-induced thrombocytopenia (HIT) market significantly, as both healthcare professionals and patients often lack sufficient knowledge about this serious condition. Furthermore, the complexity of HIT management requires specialized knowledge regarding alternative anticoagulants and monitoring protocols, which can be challenging in settings where healthcare providers are not adequately trained. Consequently, this limited awareness can restrict market growth by reducing the demand for effective treatments and hindering the development of comprehensive care strategies for HIT management.

Segment Analysis

The global heparin induced thrombocytopenia market is segmented based on drugs, route of administration, end-user, and region.

Drugs:

Argatroban is expected to dominate the global heparin induced thrombocytopenia market share

Argatroban is expected to dominate the heparin-induced thrombocytopenia (HIT) market due to its unique properties as a direct thrombin inhibitor and its established efficacy in treating this serious condition. As a non-heparin anticoagulant, argatroban is particularly valuable for patients with HIT, where traditional heparin therapy poses significant risks. Its intravenous administration allows for rapid onset of action, making it suitable for emergency settings, especially in hospitals where timely treatment is crucial.

The market for argatroban is projected to grow significantly, driven by an increasing incidence of HIT and rising awareness among healthcare professionals regarding its benefits. Additionally, argatroban's favorable safety profile and effectiveness in patients with renal dysfunction further enhance its appeal as a preferred treatment option. With ongoing clinical studies and potential new indications being explored, argatroban is well-positioned to capture a substantial share of the HIT treatment market in the coming years, reinforcing its role as a key therapeutic agent in managing this condition effectively.

Geographical Analysis

North America is expected to hold a significant position in the global heparin induced thrombocytopenia market share

North America is expected to dominate the heparin-induced thrombocytopenia (HIT) market due to its advanced healthcare infrastructure, high levels of awareness among healthcare professionals, and a significant patient population at risk for HIT. The region accounted for the largest market driven by the increasing incidence of conditions requiring heparin therapy, such as cardiovascular diseases and surgeries.

North American healthcare providers are well-equipped to accurately diagnose and manage HIT, facilitating timely interventions that improve patient outcomes. Furthermore, ongoing research and development efforts in anticoagulant therapies are concentrated in this region, supported by robust regulatory frameworks and funding initiatives. The presence of key pharmaceutical players also enhances innovation and the availability of effective treatment options. As a result, North America is projected to maintain its leadership position in the HIT market, with continued growth anticipated through increased awareness and improved treatment protocols.

Competitive Landscape

The major global players in the heparin induced thrombocytopenia market include Pfizer Inc., Novartis AG, Eagle Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, GLAND PHARMA Ltd., Teva Pharmaceutical Industries Ltd. and Verolax Therapeutics among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Heparin Induced Thrombocytopenia Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drugs
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing usage of heparin
  • 4.1.2. Restraints
    • 4.1.2.1. Limited awareness of the disease
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Argatroban*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Lepirudin

7. By Route of Administration

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 7.1.2. Market Attractiveness Index, By Route of Administration
• 7.2. Parenteral*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Oral

8. By End-User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 8.1.2. Market Attractiveness Index, By End-User
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Specialty Clinics
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

Key Market Players

• 11.1. Pfizer Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio
    • 11.1.2.1. Product Description
    • 11.1.2.2. Product Key Performance Indicators (KPIs)
    • 11.1.2.3. Historic and Forecasted Product Sales
    • 11.1.2.4. Product Sales Volume
  • 11.1.3. Financial Overview
    • 11.1.3.1. Company Revenue's
    • 11.1.3.2. Geographical Revenue Shares
    • 11.1.3.3. Revenue Forecasts
  • 11.1.4. Key Developments
    • 11.1.4.1. Mergers & Acquisitions
    • 11.1.4.2. Key Product Development Activities
    • 11.1.4.3. Regulatory Approvals etc.
  • 11.1.5. SWOT Analysis
• 11.2. Novartis AG
• 11.3. Eagle Pharmaceuticals, Inc.
• 11.4. Mitsubishi Chemical Group Corporation
• 11.5. GLAND PHARMA Ltd.
• 11.6. Teva Pharmaceutical Industries Ltd.
• 11.7. Verolax Therapeutics
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us